You just read:

New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations

News provided by

Boehringer Ingelheim Pharmaceuticals, Inc.

Dec 09, 2010, 08:45 EST